- From: Eric Prud'hommeaux <eric@w3.org>
- Date: Tue, 21 Feb 2012 12:25:09 -0500
- To: w3c semweb hcls <public-semweb-lifesci@w3.org>
http://www.w3.org/2012/02/21-HCLS-minutes [1]W3C HCLS IG weekly: HCLS Pharmceutical in Clinical Research 21 Feb 2012 See also: [2]IRC log Attendees Present Regrets Chair Vijay Bulusu Scribe ericP Contents * [3]Topics 1. [4]Vijay introduction 2. [5]Systems Biology for Drug Discovery 3. [6]Pharmacogenomics 4. [7]recruitment 5. [8]task force for rendering experimental information in an open manner * [9]Summary of Action Items __________________________________________________________________ Vijay introduction vbulusu: work in pharma ... invited by ericP to chair HCLS ... the cochairs and ericP discussed domain-specific calls for: ... .. interest to industry ... .. task force coodination ... there are two TFs in this focus: ... .. Systems Bio, chair: Helena Deus ... .. Pharmacogenomics, chair: Michel Dumontier ... looking for new ideas and use cases for these task forces ... will discuss a new task force for which I'm recruiting members [10]Systems Biology for Drug Discovery Helena: in Bio, many things go wrong at the pathway level ... e.g. signally pathway failures result in cancer ... so we'll look at data made available by TCGA ... RDF-izing the 8.3TB of TCGA is unreallistic ... instead we'll take data from 8 or 9 interesting proteins ... annotate the proteins with results [from TCGA] ... we need to look for TCGA resources and extract the 8 or 9 target proteins ... first telco this week ... at the beginning, we'll be recruiting participants ... i've heard lots of interest vbulusu: who do you have alread? Helena: Jun Zao, ericP, Michael Miller (Institute for Systems Bio) ... hoping to recruit more bioinformatisists (as opposed to computer geeks) vbulusu: overlap with Sylventa's [11]BEL Framework? Helena: there's a lot of overlap. expect to use their vocabs ... they're not annotating experimental data as far as i know ... michel demo'd SBML last week. should be relevent ericP: Ted Slater described thinking of BEL in terms of a surface syntax for RDF ACTION: ericP to connect Ted Slater to Helena [recorded in [12]http://www.w3.org/2012/02/21-HCLS-minutes.html#action01] ACTION: ericP to connect Dave Hau to Helena [recorded in [13]http://www.w3.org/2012/02/21-HCLS-minutes.html#action02] mscottm2: Sylventa said they wanted to put BEL forward as a standard. have they come to W3C? ericP: they spoke about the openness in a presentation at the Cambridge Semantic Web Gathering Helena: my current wiki page is about recruitment ... people in this group expect to work bottom-up ... people say what they expect to achieve michel: would like to see some structure, expected outcomes Helena: i can add vision and goals to the wiki vbulusu: adding the members will help ... do you need pharma folks? Helena: desparately vbulusu: bioinformatics and systems bio focus? Helena: the bioinformatics is just how to glue stuff together ... exploring our models to see if we can learn stuff about the biology ACTION: vbulusu to recruit in pharma for Systems Biology for Drug Discovery [recorded in [14]http://www.w3.org/2012/02/21-HCLS-minutes.html#action03] michel: IO-Informatics might be interested Helena: will reach out to Eric Gombocz Pharmacogenomics michel: we'll be looking at data related to pharmacogenomics ... e.g. ... .. patient stratification ... .. risk assessment ... .. dosing ... gathering related data, e.g.: ... .. clinical trial outcome ... .. efficacy ... we can marshal data from e.g. PharmGKB, or clinical trial ... wherever we can map genotype to phenotype ... idea is that we have a pharmacogenomics KB ... i got clinical annotation from PharmGKB ... PGKB license issue: ... .. you need to apply for access ... .. you can't redistribute ... maybe we can negotiate, but barring that, we can make available the [triplifying] scripts ... we want to ask questions of the KB, with inference ... will support Clinical Decision Support ... we have folks from: ... .. mayo clinic ... .. variety of academic institutions ... missing industry, e.g. those interested in clinical trials or FDA [,EMA] submissions, adverse event reporting vbulusu: looking at use cases, have you looked at how to select a smaller set of use cases? michel: this [wiki] list is from the relevent TMO use cases ... some from IO-Informatics, and mscottm2 had breast cancer use cases ... so yes, we need to identify a small set ... potentially, each individual can set up a use case which drives their personal interests ... i expect significant overlap due to the paucity of data ... gene expression, DBSNP, performance of (anti-rejection) drugs ericP: feel free to be a tyrant vbulusu: pharma focused on precision medicine ... mostly these folks would be interested in joining the HCLS community where it can give them quick answers recruitment michel: we can ask industry what they need done, and peridically get sanity checks ... but in the end, we want assurances of adoption mscottm2: great if you can find someone in a hospital or pharma setting who's not expecting a shrink-wrapped solution ... get them to bring us interesting problems ... most folks in those settings don't see the prob with working in monolithic applications <mscottm2> someone who can bring a problem for us to solve and become a sort of 'client' Helena: have you looked at pharmacoglycomics? michel: looked at some sugars when i was an undergrad ... know folks at bioCanada who look at e.g. qualitiy of peptides ... Helena: if you know the glycosylation pattern, you can predict binding task force for rendering experimental information in an open manner vbulusu: in 2009, [15]Pistoia started an Electronic Lab Notebook working group to exploit the info captured in (different) ELNs ... also to share info in the pharma with other organizations ... looking at what they've done, they worked for a year trying to create ELN standards so that e.g. CambridgeSoft data could work with Exceleris vbulusu: they stopped in early 2011 when some members didn't adopt and proposed standards ... need is still out there. ... pharmas need to exchange with Clinical Research Organizations ... every pharma will say they need standards in this space ... expect to start with medicinal chemistry, not biology <mscottm2> ericP: access control in ELN for example for CROs, capture somethings in BEL framework. [16]strawman research pipeline document <michel> [17]http://www.sciencedirect.com/science/article/pii/S1359644609000737 michel: met Jeremy Fray (S'Hampton) has been working on chem lab notebooks ... he's got a representation for synthetic chemistry ... track whether you are doing stuff in the right order, and what are the values you're obtaining <mscottm2> Michel mentions Peter Murray-Rust / Cambridge (Open Knowledge Foundation) in the context of patents michel: Peter Murray Rust validates patents by seeing if the chemical processes follow a single transformation vbulusu: looked at Rust, and Jeremy's work is definitely in line. good connections michel: i don't think Jeremy focuses on inferencing; just capture for later SPARQL query ... BEL may be more focused on inferencing a(foo) upregulates b(c(bar)) . Summary of Action Items [NEW] ACTION: ericP to connect Dave Hau to Helena [recorded in [18]http://www.w3.org/2012/02/21-HCLS-minutes.html#action02] [NEW] ACTION: ericP to connect Ted Slater to Helena [recorded in [19]http://www.w3.org/2012/02/21-HCLS-minutes.html#action01] [NEW] ACTION: vbulusu to recruit in pharma for Systems Biology for Drug Discovery [recorded in [20]http://www.w3.org/2012/02/21-HCLS-minutes.html#action03] [End of minutes] __________________________________________________________________ Minutes formatted by David Booth's [21]scribe.perl version 1.136 ([22]CVS log) $Date: 2012/02/21 17:22:00 $ __________________________________________________________________ References 1. http://www.w3.org/ 2. http://www.w3.org/2012/02/21-HCLS-irc 3. http://www.w3.org/2012/02/21-HCLS-minutes#agenda 4. http://www.w3.org/2012/02/21-HCLS-minutes#item01 5. http://www.w3.org/2012/02/21-HCLS-minutes#item02 6. http://www.w3.org/2012/02/21-HCLS-minutes#item03 7. http://www.w3.org/2012/02/21-HCLS-minutes#item04 8. http://www.w3.org/2012/02/21-HCLS-minutes#item05 9. http://www.w3.org/2012/02/21-HCLS-minutes#ActionSummary 10. http://www.w3.org/wiki/HCLSIG/SysBio 11. http://selventa.com/technology/bel-framework 12. http://www.w3.org/2012/02/21-HCLS-minutes.html#action01 13. http://www.w3.org/2012/02/21-HCLS-minutes.html#action02 14. http://www.w3.org/2012/02/21-HCLS-minutes.html#action03 15. http://www.pistoiaalliance.org/ 16. http://www.w3.org/2012/hcls-resources/pipeline.svg 17. http://www.sciencedirect.com/science/article/pii/S1359644609000737 18. http://www.w3.org/2012/02/21-HCLS-minutes.html#action02 19. http://www.w3.org/2012/02/21-HCLS-minutes.html#action01 20. http://www.w3.org/2012/02/21-HCLS-minutes.html#action03 21. http://dev.w3.org/cvsweb/~checkout~/2002/scribe/scribedoc.htm 22. http://dev.w3.org/cvsweb/2002/scribe/ 23. http://dev.w3.org/cvsweb/~checkout~/2002/scribe/ 24. http://www.w3.org/2012/02/21-HCLS-minutes.html 25. http://dev.w3.org/cvsweb/~checkout~/2002/scribe/scribedoc.htm -- -ericP
Received on Tuesday, 21 February 2012 17:25:45 UTC